optic atrophy 1 opa1  (Novus Biologicals)

Journal: Animal Models and Experimental Medicine

Article Title: Overexpression of mitofusin 2 ameliorates inflammation and oxidative stress in lipopolysaccharide‐induced mastitis model by regulating phosphofurin acidic cluster sorting protein 2

doi: 10.1002/ame2.70110

Figure Lengend Snippet: LPS (lipopolysaccharide) modulates mitochondrial‐ER (endoplasmic reticulum) membrane protein expression and disrupts MAM (mitochondria‐associated endoplasmic reticulum membrane) integrity. (A and B) Protein expression and quantification of MFN2 (mitofusin 2) in mouse mammary epithelial cells (mMEC) detected using Western blot. (C–F) Protein expression and quantification of FIS‐1 (fission protein 1), DRP‐1 (dynamin‐related protein 1), and OPA‐1 (optic atrophy 1) in mMECs detected using Western blot. (G–I) Protein expression and quantification of eIF‐2α (eukaryotic translation initiation factor 2 alpha), p‐eIF‐2α, and PACS2 (phosphofurin acidic cluster sorting protein 2) in mMECs. (J) Protein expression of MFN2 and PACS2 in mMECs after LPS stimulation detected using immunofluorescence. (K) Mitochondrial and ER marker protein PDI (protein disulfide isomerase) expression detected using laser confocal microscopy. Data are presented as mean ± SD (standard deviation).

Article Snippet: Optic atrophy 1 , 80471 , 1:2000 , Cell Signaling Technology.

Techniques: Membrane, Expressing, Western Blot, Immunofluorescence, Marker, Confocal Microscopy, Standard Deviation

Journal: Animal Models and Experimental Medicine

Article Title: Overexpression of mitofusin 2 ameliorates inflammation and oxidative stress in lipopolysaccharide‐induced mastitis model by regulating phosphofurin acidic cluster sorting protein 2

doi: 10.1002/ame2.70110

Figure Lengend Snippet: MFN2‐PACS2 (mitofusin 2–phosphofurin acidic cluster sorting protein 2) interaction regulates MAM (mitochondria‐associated endoplasmic reticulum membrane) dynamics and mitigates LPS (lipopolysaccharide)–induced mitochondrial dysfunction. (A) CO‐IP (co‐immunoprecipitation) of MFN2 in mouse mammary epithelial cell (mMEC) lysates. (B) Immunoprecipitation of MFN2 in mMEC lysates. OE‐MFN2 denotes MFN2 overexpression. (C) Immunoprecipitation of MFN2 in mMEC lysates. (D) CO‐IP of PACS2 in mMEC lysates. (E) mRNA (messenger RNA) expression of MFN2 in mammary tissues detected using qRT‐PCR (quantitative reverse transcription polymerase chain reaction). (F) Immunoprecipitation of MFN2 in mMEC lysates. (G) Protein expression and quantification of DRP‐1 (dynamin‐related protein 1), OPA‐1 (optic atrophy 1), FIS‐1 (fission protein 1), and MFN1 in mMECs detected using Western blot. (H and I) Mitochondrial and ER marker protein PDI (protein disulfide isomerase) expression detected using laser confocal microscopy.

Article Snippet: Optic atrophy 1 , 80471 , 1:2000 , Cell Signaling Technology.

Techniques: Membrane, Co-Immunoprecipitation Assay, Immunoprecipitation, Over Expression, RNA Expression, Quantitative RT-PCR, Reverse Transcription, Polymerase Chain Reaction, Expressing, Western Blot, Marker, Confocal Microscopy

Journal: Genes & Diseases

Article Title: Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A

doi: 10.1016/j.gendis.2025.101761

Figure Lengend Snippet: Oxidative phosphorylation was down-regulated after tirzepatide treatment. Transcriptomic sequencing was performed on liver tissues from three groups of mice: the NCD, HFFC, and HFFC with tirzepatide treatment groups. (A) Principal component analysis. (B) Volcano plot of differential expression. (C) KEGG enrichment analysis was performed on the differentially expressed genes between the HFFC group and the HFFC with tirzepatide treatment group. (D) Cluster analysis was performed on the genes involved in the reactive oxygen species and oxidative phosphorylation pathways across the NCD, HFFC, and HFFC with tirzepatide treatment groups. (E) Quantitative PCR was performed to validate the expression of genes in this pathway, including Atp5mc2, Gsta2, Nox4, Slc26a2, Hif1α, and Cycs. (F) Western blot analysis was used to detect Cyc protein expression in liver tissues from the NCD, HFD, HFFC, and HFD or HFFC with tirzepatide treatment groups. (G) Western blot analysis was used to detect the protein expression levels of ATP5A1, UQCRC1, SDHB, MTCO2, NDUFB8, and COX4 in liver tissues from the NCD, HFD, HFFC, and HFD or HFFC with tirzepatide treatment groups. (H) OPA1 protein expression was analyzed via western blotting. n = 5. The data are presented as mean ± SD.

Article Snippet: Optic atrophy protein 1 (OPA1) antibody (1:1000, cat. ET1705-9), COX IV antibody (1:2000, cat. ET1701-63), cytochrome C antibody (1:3000, cat. ET1610-16) and adipose triglyceride lipase antibody (1:1000, cat. HA721951) was obtained from HUABIO Biotechnology (Hangzhou, China).

Techniques: Phospho-proteomics, Sequencing, Quantitative Proteomics, Real-time Polymerase Chain Reaction, Expressing, Western Blot

Journal: Life sciences

Article Title: Chronic administration of the hydrogen sulfide prodrug SG1002 partially protects against erectile dysfunction resulting from long-term androgen deprivation

doi: 10.1016/j.lfs.2025.123976

Figure Lengend Snippet: The expression of proteins related to mitochondrial dynamics in mouse corpus cavernosum measured by western blot. Mice underwent sham surgery (Sham) or were surgically castrated (Cast). Two groups of castrated mice were treated with low-dose (CLS) or high-dose (CHS) SG1002. Proteins include mitofusin 1 (Mfn1), mitofusin 2 (Mfn2), optic atrophy type 1 (Opa1), dynamin-related protein 1 (Drp1), and mitochondrial fission 1 (Fis1). Protein expression was normalized to GAPDH. Values represent means ± SEM for n = 12 animals per group. * p < 0.05 compared to Sham.

Article Snippet: Primary antibodies were obtained from Cell Signaling Technologies (CST; Danvers, MA, USA), or Protein Tech (PT; Rosemount, IL, USA) and used at the following dilutions: glutamate-cysteine ligase (Gclc, PT #12601–1-AP, 1:1000), optic atrophy type 1 (Opa1, CST #80471, 1:1000), peroxiredoxin 3 (Prdx3, PT #10664–1-AP, 1:1000), peroxiredoxin 5 (Prdx5, PT #17724–1-AP, 1:1000), mitofusin 1 (Mfn1, PT #13798–1-AP, 1:1000), mitofusin 2 (Mfn2, PT #12186–1-AP, 1:1000), NAD(P)H dehydrogenase quinone 1 (Nqo1, CST #62262, 1:1000), thioredoxin 1 (Trx1, CST #2298, 1:1000), thioredoxin-interacting protein (Txnip, PT #18243–1-AP, 1:1000), thioredoxin 2 (Trx2, CST #14907, 1:1000), dynamin-related protein 1 (Drp1, CST #8570, 1:1000), superoxide dismutase 1 (Sod1, PT #10269–1-AP, 1:1000), superoxide dismutase 2 (Sod2, CST #13141, 1:2000), superoxide dismutase 3 (Sod3, Santa Cruz Biotechnology #sc-271170, 1:1000) autophagy-related protein (Atg7, CST #8558, 1:1000), mitochondrial fission 1 (Fis1, PT #10956–1-AP, 1:1000), phosphorylated (Ser 403 ) Sequestosome-1 (P-Sqstm1/p62, CST #39786, 1:1000), sequestosome-1 (Sqstm1/p62, CST #39749, 1:1000), heme oxygenase 1 (HO-1, PT #10701–1-AP, 1:1000), light chain 3B (LC3B, CST #2775, 1:1000), GAPDH (PT #60004–1-Ig, 1:4000).

Techniques: Expressing, Western Blot